DNA demethylation and invasive cancer: implications for therapeutics.

  title={DNA demethylation and invasive cancer: implications for therapeutics.},
  author={David Cheishvili and Lisa Boureau and Moshe Szyf},
  journal={British journal of pharmacology},
  volume={172 11},
One of the hallmarks of cancer is aberrant DNA methylation, which is associated with abnormal gene expression. Both hypermethylation and silencing of tumour suppressor genes as well as hypomethylation and activation of prometastatic genes are characteristic of cancer cells. As DNA methylation is reversible, DNA methylation inhibitors were tested as anticancer drugs with the idea that such agents would demethylate and reactivate tumour suppressor genes. Two cytosine analogues, 5-azacytidine… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
11 Extracted Citations
87 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 11 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 87 references

domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. Journal of molecular biology

  • P Fenaux, N Gattermann, JF Seymour, E Hellstrom-Lindberg, GJ Mufti, U Duehrsen
  • 2010
Highly Influential
8 Excerpts

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

  • F Santos, J Peat, H Burgess, C Rada, W Reik, W Dean
  • J Clin Oncol
  • 2013
Highly Influential
5 Excerpts

Ezrin gene

  • H e12710. Zhang, F Qi, Y Cao, X Zu, M Chen, Z Li
  • 2013
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…